MX360706B - Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. - Google Patents
Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.Info
- Publication number
- MX360706B MX360706B MX2014004253A MX2014004253A MX360706B MX 360706 B MX360706 B MX 360706B MX 2014004253 A MX2014004253 A MX 2014004253A MX 2014004253 A MX2014004253 A MX 2014004253A MX 360706 B MX360706 B MX 360706B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- arylcarbonyl
- oxy
- neurodegenerative diseases
- compounds useful
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de utilidad como un agente para la prevención o el tratamiento de enfermedad neurodegenerativa, y similares o una de sus sales. La presente invención se refiere a un compuesto representado por la fórmula (I) en donde cada símbolo es como se define en la descripción, o una de sus sales. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011222741 | 2011-10-07 | ||
| PCT/JP2012/076257 WO2013054822A1 (en) | 2011-10-07 | 2012-10-03 | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014004253A MX2014004253A (es) | 2014-06-11 |
| MX360706B true MX360706B (es) | 2018-11-14 |
Family
ID=47143241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004253A MX360706B (es) | 2011-10-07 | 2012-10-03 | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
Country Status (43)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX360706B (es) | 2011-10-07 | 2018-11-14 | Takeda Pharmaceuticals Co | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
| WO2014061676A1 (ja) | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
| CR20150364A (es) | 2012-12-11 | 2016-09-20 | Takeda Pharmaceuticals Co | Compuesto heterociclico |
| CN105246486B (zh) | 2013-03-13 | 2020-11-03 | 萨奇治疗股份有限公司 | 神经活性甾类化合物 |
| WO2014163162A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2014163161A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3152198B1 (en) * | 2014-06-09 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| CN104803922A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种嘧啶衍生物的制备方法 |
| KR20240166589A (ko) | 2015-07-06 | 2024-11-26 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| ES2865258T3 (es) | 2015-07-06 | 2021-10-15 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| JP6807322B2 (ja) * | 2015-10-16 | 2021-01-06 | 武田薬品工業株式会社 | 複素環化合物の製造方法 |
| GB201604029D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN109071440A (zh) * | 2016-05-13 | 2018-12-21 | 日产化学株式会社 | 2-乙酰基吡啶化合物的制造方法 |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| JP7196157B2 (ja) * | 2017-08-31 | 2022-12-26 | 武田薬品工業株式会社 | Ｃｎｓ状態の治療 |
| WO2020027344A1 (en) * | 2018-08-03 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for mdd use |
| EP3852757A1 (en) * | 2018-09-20 | 2021-07-28 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for pain use |
| TW202523658A (zh) * | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| JP2023550654A (ja) * | 2020-11-25 | 2023-12-04 | セージ セラピューティクス， インコーポレイテッド | 神経変性障害の治療のためのｃｙｐ４６ａ１阻害剤としての４－フルオロ－（４－（４－ベンジル）ピペリジン－１－イル）（２－（ピリミジン－４－イル）ピリジン－３－イル）メタノン誘導体および類似化合物 |
| IL309208A (en) | 2021-06-11 | 2024-02-01 | Sage Therapeutics Inc | Neuroactive steroid for the treatment of alzheimer's disease |
| AU2022410646A1 (en) * | 2021-12-17 | 2024-05-30 | Athira Pharma, Inc. | Uses of bicyclic compounds for the treatment of diseases |
| CN116444477B (zh) * | 2023-04-04 | 2026-01-02 | 宁波九胜创新医药科技有限公司 | 一种溴代胡椒环羧酸的制备方法及其用途 |
| WO2025019590A2 (en) * | 2023-07-18 | 2025-01-23 | The General Hospital Corporation | Proteolysis targeting chimeras for treating neurodegeneration |
| WO2025126159A1 (en) | 2023-12-15 | 2025-06-19 | Takeda Pharmaceutical Company Limited | A method for treating a neurological disease in a recreational drug user |
| WO2025257799A1 (en) | 2024-06-14 | 2025-12-18 | Takeda Pharmaceutical Company Limited | Methods of treating dravet syndrome |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| ES2245003T3 (es) | 1996-08-27 | 2005-12-16 | Praecis Pharmaceuticals Incorporated | Moduladores de la agregacion de peptidos beta-amiloides que comprenden d-aminoacidos. |
| ATE482233T1 (de) | 1999-06-28 | 2010-10-15 | Oklahoma Med Res Found | Inhibitoren des memapsin 2 und ihre verwendung |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1285651B1 (en) | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonists |
| AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
| AU2002248432A1 (en) | 2001-02-14 | 2002-08-28 | Sankyo Company, Limited | Oxazole derivatives, their preparation and their use as cytokine inhibitors |
| CA2445568A1 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| DOP2005000039A (es) | 2004-03-26 | 2005-10-31 | Aventis Pharma Inc | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
| US20060167044A1 (en) | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| WO2006137465A1 (ja) | 2005-06-24 | 2006-12-28 | Shionogi & Co., Ltd. | 含窒素複素環誘導体 |
| BRPI0619268A2 (pt) * | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
| NZ569108A (en) | 2005-12-20 | 2011-09-30 | Bristol Myers Squibb Co | Formulations of CTLA4Ig stabilised using sugars |
| AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
| WO2008134547A1 (en) | 2007-04-25 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions |
| WO2008153722A1 (en) | 2007-05-22 | 2008-12-18 | The Board Of Regents Of The University Of Texas System | Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof |
| WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| RS54413B1 (sr) | 2008-08-22 | 2016-04-28 | Sanofi | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita |
| EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
| DE102009022896A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| DE102009022894A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
| JP5316468B2 (ja) | 2010-04-09 | 2013-10-16 | 株式会社豊田自動織機 | リアクトル構造 |
| EA025611B1 (ru) | 2010-07-29 | 2017-01-30 | Райджел Фармасьютикалз, Инк. | Активирующие ampk гетероциклические соединения и способы их использования |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| MX360706B (es) * | 2011-10-07 | 2018-11-14 | Takeda Pharmaceuticals Co | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
-
2012
- 2012-10-03 MX MX2014004253A patent/MX360706B/es active IP Right Grant
- 2012-10-03 CA CA2851087A patent/CA2851087C/en active Active
- 2012-10-03 AP AP2014007606A patent/AP2014007606A0/xx unknown
- 2012-10-03 TR TR2019/02788T patent/TR201902788T4/tr unknown
- 2012-10-03 EA EA201490747A patent/EA025662B1/ru not_active IP Right Cessation
- 2012-10-03 TW TW101136475A patent/TWI582084B/zh active
- 2012-10-03 UA UAA201404855A patent/UA115133C2/uk unknown
- 2012-10-03 PL PL12781479T patent/PL2763979T3/pl unknown
- 2012-10-03 BR BR112014007257-4A patent/BR112014007257B1/pt active IP Right Grant
- 2012-10-03 LT LTEP12781479.6T patent/LT2763979T/lt unknown
- 2012-10-03 WO PCT/JP2012/076257 patent/WO2013054822A1/en not_active Ceased
- 2012-10-03 PE PE2014000466A patent/PE20141120A1/es active IP Right Grant
- 2012-10-03 PH PH1/2014/500759A patent/PH12014500759A1/en unknown
- 2012-10-03 HU HUE12781479A patent/HUE043171T2/hu unknown
- 2012-10-03 SM SM20190173T patent/SMT201900173T1/it unknown
- 2012-10-03 SG SG2014010417A patent/SG2014010417A/en unknown
- 2012-10-03 UY UY0001034365A patent/UY34365A/es not_active Application Discontinuation
- 2012-10-03 DK DK12781479.6T patent/DK2763979T3/en active
- 2012-10-03 US US13/633,995 patent/US8648079B2/en active Active
- 2012-10-03 ME MEP-2019-69A patent/ME03372B/me unknown
- 2012-10-03 JP JP2014513813A patent/JP6117191B2/ja active Active
- 2012-10-03 ES ES12781479T patent/ES2716531T3/es active Active
- 2012-10-03 AR ARP120103691A patent/AR088226A1/es active IP Right Grant
- 2012-10-03 BR BR122022001219-1A patent/BR122022001219B1/pt active IP Right Grant
- 2012-10-03 MY MYPI2014700836A patent/MY176126A/en unknown
- 2012-10-03 HR HRP20190491TT patent/HRP20190491T1/hr unknown
- 2012-10-03 PT PT12781479T patent/PT2763979T/pt unknown
- 2012-10-03 EP EP12781479.6A patent/EP2763979B1/en active Active
- 2012-10-03 KR KR1020147011963A patent/KR101967497B1/ko active Active
- 2012-10-03 GE GEAP201213457A patent/GEP201706608B/en unknown
- 2012-10-03 SI SI201231548T patent/SI2763979T1/sl unknown
- 2012-10-03 RS RS20190304A patent/RS58470B1/sr unknown
- 2012-10-03 CN CN201280049068.8A patent/CN103842356B/zh active Active
- 2012-10-03 AU AU2012321815A patent/AU2012321815B2/en active Active
- 2012-10-03 US US14/349,201 patent/US9193709B2/en active Active
-
2013
- 2013-07-17 US US13/944,000 patent/US8865717B2/en active Active
- 2013-07-17 US US13/944,042 patent/US8871766B2/en active Active
-
2014
- 2014-03-24 IL IL231678A patent/IL231678A/en active IP Right Grant
- 2014-03-25 TN TNP2014000122A patent/TN2014000122A1/en unknown
- 2014-04-02 ZA ZA2014/02424A patent/ZA201402424B/en unknown
- 2014-04-02 CL CL2014000806A patent/CL2014000806A1/es unknown
- 2014-04-03 CR CR20140151A patent/CR20140151A/es unknown
- 2014-04-04 DO DO2014000064A patent/DOP2014000064A/es unknown
- 2014-04-29 EC ECSP14013329 patent/ECSP14013329A/es unknown
- 2014-05-02 CO CO14094354A patent/CO6940432A2/es unknown
- 2014-05-04 MA MA36973A patent/MA35623B1/fr unknown
-
2015
- 2015-09-08 US US14/847,703 patent/US9440990B2/en active Active
-
2016
- 2016-07-28 US US15/221,761 patent/US9586930B2/en active Active
-
2017
- 2017-02-03 US US15/424,075 patent/US10144743B2/en active Active
-
2018
- 2018-11-19 US US16/194,540 patent/US10273245B2/en active Active
-
2019
- 2019-03-18 CY CY20191100324T patent/CY1121549T1/el unknown
- 2019-04-11 US US16/381,163 patent/US10550129B2/en active Active
-
2020
- 2020-02-03 US US16/779,797 patent/US10717748B2/en active Active
- 2020-07-20 US US16/933,092 patent/US11174272B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| MY164776A (en) | Heterocyclic compound | |
| PH12015501316A1 (en) | Heterocyclic compound | |
| PH12013501099A1 (en) | Bicyclic compound | |
| MX343561B (es) | Compuestos de imidazolpiridazina. | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| UA114611C2 (uk) | Пестицидні композиції і способи, що їх стосуються | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| MX352928B (es) | Compuestos de piridazina-amida. | |
| MX342310B (es) | Compuestos de tiazolopirimidina. | |
| PH12014502396B1 (en) | Nitrogenated heterocyclic compound | |
| IN2014CN04558A (es) | ||
| IN2014CN04449A (es) | ||
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| IN2014DN01629A (es) | ||
| UA113086C2 (xx) | Піразольні сполуки як інгібітори sglt1 | |
| NZ707773A (en) | Methods of treating liver diseases | |
| SG10201901578UA (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
| EA033160B1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| JO3723B1 (ar) | مركبات دائرية مغايرة | |
| TN2013000230A1 (en) | Bicyclic compound | |
| MX2011012511A (es) | Anti-oomicetos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |